News headlines about Otonomy (NASDAQ:OTIC) have trended somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Otonomy earned a news sentiment score of 0.10 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 44.874476058578 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Shares of Otonomy (NASDAQ:OTIC) traded up 1.45% during trading on Thursday, hitting $3.50. The company had a trading volume of 659,097 shares. The stock’s market capitalization is $106.06 million. The stock has a 50-day moving average of $5.36 and a 200 day moving average of $13.00. Otonomy has a 12-month low of $3.15 and a 12-month high of $21.15.
Otonomy (NASDAQ:OTIC) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.77) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.80) by $0.03. Otonomy had a negative return on equity of 57.43% and a negative net margin of 8,172.38%. The firm had revenue of $0.33 million during the quarter, compared to analysts’ expectations of $0.43 million. During the same quarter last year, the firm posted ($0.98) earnings per share. The company’s revenue for the quarter was up 312.5% compared to the same quarter last year. On average, analysts predict that Otonomy will post ($3.23) EPS for the current fiscal year.
Several equities analysts have recently issued reports on the company. BidaskClub lowered Otonomy from a “buy” rating to a “hold” rating in a research report on Friday, August 11th. Zacks Investment Research upgraded Otonomy from a “sell” rating to a “hold” rating in a research report on Friday, August 18th. J P Morgan Chase & Co upgraded Otonomy from a “neutral” rating to an “overweight” rating and set a $28.00 target price for the company in a research report on Tuesday, August 15th. Cowen and Company restated an “outperform” rating and set a $55.00 target price on shares of Otonomy in a research report on Wednesday, August 23rd. Finally, Piper Jaffray Companies restated an “overweight” rating and set a $32.00 target price on shares of Otonomy in a research report on Friday, June 30th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $10.00.
Otonomy, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company’s product candidates include OTIPRIO, OTO-104 and OTO-311. OTIPRIO is a single-dose, physician-administered antibacterial, which is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery and is available for commercial purchase.
Receive News & Ratings for Otonomy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.